ArticleFrontiers in immunology2026
Myelin oligodendrocyte glycoprotein antibody-associated isolated seizures in children: a retrospective single-center case series.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Isolated seizures represent a distinct, rare, and underrecognized phenotype of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). In recent years, documentation of this phenotype has been limited to sporadic reports, with dedicated case series being extremely scarce. This study aimed to describe the clinical characteristics of isolated seizures in pediatric patients with MOGAD. Methods: We retrospectively reviewed the medical records of pediatric patients diagnosed with MOG antibody-associated isolated seizures between January 2019 and January 2026. Clinical manifestations, brain magnetic resonance imaging (MRI) findings, laboratory data, treatment regimens, and clinical outcomes were systematically analyzed. Results: Among the cohort of 172 pediatric patients with seropositive MOG antibodies, 6 (3.4%) met the inclusion criteria for isolated seizures. The median age at onset was 7.5 years (range, 5-9 years), with a male-to-female ratio of 1:2. Clinically, 4 patients presented solely with epileptic seizures, while the other 2 patients had additional transient limb weakness or headache, respectively. Focal seizures were observed in 5 patients, including 3 with focal motor seizures; additionally, 2 cases experienced status epilepticus. No patients exhibited encephalopathy or focal neurological deficits. Four patients had peripheral blood leukocytosis (range, 11.9-26 × 10 Conclusion: Myelin oligodendrocyte glycoprotein antibody-associated isolated seizures is a rare and frequently underrecognized phenotype within the spectrum of MOGAD. For school-age children presenting with epileptic seizures, particularly focal motor seizures, along with elevated ESR and CSF pleocytosis, early testing for MOG antibody is recommended in the absence of clinical or radiological evidence of encephalitis or focal neurological deficits. Most patients achieve favorable clinical outcomes, which may be partially attributed to immunotherapy. However, the efficacy of immunotherapy in preventing seizure recurrence, subsequent demyelinating events, and subclinical radiological disease remains indeterminate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.